AI Article Synopsis
- FDG-PET/CT is crucial in managing lymphoma patients, aiding in staging and evaluating treatment response.
- Efforts have been made to standardize PET acquisition and reporting, particularly through the use of the 5-point Deauville scale, which helps determine treatment success or failure.
- The review discusses clinical trial evidence supporting PET-directed treatment personalization in lymphoma and suggests the potential for new PET metrics and radiopharmaceuticals in future applications.
Article Abstract
18F-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is an essential part of the management of patients with lymphoma at staging and response evaluation. Efforts to standardize PET acquisition and reporting, including the 5-point Deauville scale, have enabled PET to become a surrogate for treatment success or failure in common lymphoma subtypes. This review summarizes the key clinical-trial evidence that supports PET-directed personalized approaches in lymphoma but also points out the potential place of innovative PET/CT metrics or new radiopharmaceuticals in the future.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533807 | PMC |
| http://dx.doi.org/10.3390/cancers13205222 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!